EpiCast Report: Fabry Disease — Epidemiology Forecast to 2024
- Pages: 29
- Published: August 2015
- Report Code: GDHCER086-15
Fabry disease is a rare X-linked inherited disorder caused by the deficiency of lysosomal enzyme a-galactosidase A (Nagueh, 2003). Fabry disease causes glycolipids such as globotriaosylceramide to accumulate in the vascular endothelium of skin, nervous system, heart and kidneys leading to inflammation and fibrosis resulting in organ dysfunction (Zarate and Hopkins, 2008). The organ dysfunction is regarded as the first clinical evidence of Fabry disease (Tsuboi et al., 2012). The symptoms of Fabry disease are typically severe in men, whereas women show variable range of symptoms with some being non symptomatic and others showing severe symptoms (Golfomitsos et al., 2012).
GlobalData epidemiologist forecast that the diagnosed prevalent cases of Fabry disease in the 7MM will increase from 4,538 diagnosed prevalent cases in 2014 to 8,037 diagnosed prevalent cases in 2024, at an AGR of 7.71% during the forecast period. Among the 7MM in 2024, the US will have the highest number of diagnosed prevalent cases of Fabry disease, with 3,540 diagnosed prevalent cases, whereas Spain will have the lowest number, with 523 diagnosed prevalent cases. In the 5EU, Germany will have the highest number of diagnosed prevalent cases of Fabry disease in 2024, with 819 diagnosed prevalent cases, and Spain will have the least number, with 523 diagnosed prevalent cases. Japan will have the highest AGR at 8.16%, while Germany will have the lowest AGR at 6.48%.
This report provides an overview of the risk factors, comorbidities/manifestations, and the global and historical epidemiological trends for Fabry disease in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK and Japan). It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of Fabry disease in these markets, segmented by age and sex. To construct the 10-year epidemiological forecast for the diagnosed prevalent cases of Fabry disease in the 7MM, GlobalData epidemiologists used data available from Fabry Support & Information Group (FSIG) for the US and the EU markets, and the data available for Japan from a population-based study conducted in Japan along with data available from FSIG for Asia-Pacific.
The Fabry Disease EpiCast Report and EpiCast Model provide an overview of the risk factors, comorbidities, and global trends for Fabry disease in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of Fabry disease segmented by sex, age (in five-year increments beginning at 0 years and ending at =85 years), and comorbidities in these markets.
The Fabry Disease epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.
The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Table of Contents
Table of Contents
1Table of Contents
1.1List of Tables
1.2List of Figures
2.3Upcoming Related Reports
3.2Risk Factors and Comorbidities/Manifestations
3.4.2Sources Not Used
3.4.3Forecast Assumptions and Methods – Diagnosed Prevalent Cases
3.5Epidemiological Forecast for Fabry disease (2014–2024)
3.5.1Diagnosed Prevalent Cases of Fabry disease
3.5.2Age-Specific Diagnosed Prevalent Cases of Fabry disease
3.5.3Sex-Specific Diagnosed Prevalent Cases of Fabry disease
3.6.1Epidemiological Forecast Insight
3.6.2Limitations of the Analysis
3.6.3Strengths of the Analysis
4.2About the Authors
4.2.3Global Director of Therapy Analysis and Epidemiology
4.2.4Global Head of Healthcare
List of Tables
Table 1: 7MM, Sources of Fabry Disease Diagnosed Prevalence Data
Table 2: 7MM, Diagnosed Prevalent Cases of Fabry Disease, All Ages, Both Sexes, N, Selected Years 2014–2024
Table 3: 7MM, Age-Specific Diagnosed Prevalent Cases of Fabry Disease, Both Sexes, N (Row %), 2014
Table 4: 7MM, Sex-Specific Diagnosed Prevalent Cases of Fabry Disease, All Ages, N (Row %), 2014
List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of Fabry Disease, All Ages, Both Sexes, N, 2014–2024
Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of Fabry Disease, Both Sexes, N, 2014
Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of Fabry Disease, All Ages, N, 2014